NeurologyLive® Friday 5 — October 13, 2023

News
Article

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 13, 2023.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Advancing Precision Medicine for Multiple Sclerosis: Mitzi Joi Williams, MD

The founder and chief executive officer of Joi Life Wellness Group Multiple Sclerosis Center provided insight on the barriers with expanding precision medicine and the need for additional biomarkers of clinical progression. [WATCH TIME: 3 minutes]

Advancing Precision Medicine for Multiple Sclerosis: Mitzi Joi Williams, MD

2: Emerging Approaches to the Treatment of Multiple Sclerosis

Experts share insights on the latest innovations in multiple sclerosis research, in highlights from a recent State of the Science SummitTM, presented by Neurology Live®.

Emerging Approaches to the Treatment of Multiple Sclerosis

3: NeuroVoices: Jessica Ailani, MD, on Emerging Research in Migraine, CGRPs, and PACAP Pathway

The director of the MedStar Georgetown Headache Center gave commentary on the advances in the treatment of migraine, ways to better utilize CGRP medications, and the introduction of PACAP-targeting agents and their relevancy.

NeuroVoices: Jessica Ailani, MD, on Emerging Research in Migraine, CGRPs, and PACAP Pathway

4: Key Insights into Multiple Sleep Latency Test Norms Using Large-Scale Data: Mark I. Boulos, MD, BSc, FRCP, CSCN, MSc

The assistant professor, department of medicine, division of neurology, Institute of Medical Science, University of Toronto, talked about the importance of establishing normal values for sleep studies, particularly the multiple sleep latency test, to help with effectively diagnosing sleep disorders. [WATCH TIME: 5 minutes]

Key Insights into Multiple Sleep Latency Test Norms Using Large-Scale Data: Mark I. Boulos, MD, BSc, FRCP, CSCN, MSc

5: FDA Action Update, September 2023: Approvals, Hold Lifted, and Clearance

The FDA was busy in September 2023, making a number of decisions on potential new therapeutic agents including granting approvals, updating a label, issuing complete response letters, granting a clearance, and lifting a clinical trial hold, among other actions.

FDA Action Update, September 2023: Approvals, Hold Lifted, and Clearance
Related Videos
Ro'ee Gilron, PhD
Monica Verduzco-Gutierrez, MD
Shahid Nimjee, MD, PhD
Peter J. McAllister, MD, FAAN
Video 6 - "Utilization of Neuroimaging in Alzheimer’s Disease"
Video 5 - "Contribution of Multiple Pathways to the Development of Alzheimer’s Disease"
Michael Levy, MD, PhD
Michael Levy, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.